ViiV Healthcare Presents Positive Data from Phase IIIb/IV Study of Dolutegravir vs Darunavir in Treatment-Naïve Adults with HIV-1

ViiV Healthcare today announced initial results from the Phase IIIb/IV FLAMINGO (ING114915) study.
Source: GSK news - Category: Pharmaceuticals Source Type: news